Eli Lilly (LLY) Short-term Investments (2016 - 2025)
Eli Lilly's Short-term Investments history spans 17 years, with the latest figure at $121.6 million for Q3 2025.
- For Q3 2025, Short-term Investments fell 18.61% year-over-year to $121.6 million; the TTM value through Sep 2025 reached $121.6 million, down 18.61%, while the annual FY2024 figure was $154.8 million, 41.89% up from the prior year.
- Short-term Investments reached $121.6 million in Q3 2025 per LLY's latest filing, down from $170.1 million in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of $170.1 million in Q2 2025 to a low of $37.1 million in Q3 2021.
- Average Short-term Investments over 5 years is $115.3 million, with a median of $123.4 million recorded in 2023.
- The largest YoY upside for Short-term Investments was 272.31% in 2021 against a maximum downside of 37.5% in 2021.
- A 5-year view of Short-term Investments shows it stood at $90.1 million in 2021, then skyrocketed by 60.71% to $144.8 million in 2022, then dropped by 24.65% to $109.1 million in 2023, then skyrocketed by 41.89% to $154.8 million in 2024, then dropped by 21.45% to $121.6 million in 2025.
- Per Business Quant, the three most recent readings for LLY's Short-term Investments are $121.6 million (Q3 2025), $170.1 million (Q2 2025), and $127.4 million (Q1 2025).